In conclusion, HMP1G NPs downregulated tumor‐derived IDO1 the AhR/STAT3/IL axis, improving KYN/TRP metabolism dysregulation, effectively overcoming metabolic immune suppression within the TME, reversing immunological tolerance in cold tumors, and sensitizing tumor cells to ICB therapy. This evidence concerns the gene IDO1 and neoplasm.